{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","groups":[{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG000","title":"140 mcg/kg"},{"description":"Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses\n\nLMB-100: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles\n\nSEL-110: administered on day 1 of each cycle for up to 4 cycles","id":"OG001","title":"100 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately one month and 25 days for the 100 mcg/kg Arm/Group, and 9 months and 28 days for the 140 mcg/kg Arm/Group.","title":"Number of Participants With Serious and Non-Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}